Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034
The ' Acute Myocardial Infarction Market Report ' by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space.
Some of the Key Facts of the Acute Myocardial Infarction Market Report:
• The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth.
• In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034.
• LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease.
• NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023.
• In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention.
• In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women.
• Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
• Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.
To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast
Acute Myocardial Infarction Overview
Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used.
AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers.
Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here:
Acute Myocardial Infarction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acute Myocardial Infarction Epidemiology Segmentation:
The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total Incident Cases of AMI
• Type-Specific Incident Cases of AMI
• Gender-Specific Incident Cases of AMI
Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast
Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities
The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acute Myocardial Infarction Market Strengths
• Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair.
• High disease burden and awareness ensure steady demand for treatment and care.
Acute Myocardial Infarction Market Weaknesses
• High treatment costs limit access in low- and middle-income regions.
• Delayed diagnosis and limited emergency care affect outcomes in underserved areas.
Scope of the Acute Myocardial Infarction Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
• Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.
• Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies
• Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement
To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report
Table of Contents
1. Acute Myocardial Infarction Market Report Introduction
2. Executive Summary for Acute Myocardial Infarction
3. SWOT analysis of Acute Myocardial Infarction
4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance
5. Acute Myocardial Infarction Market Overview at a Glance
6. Acute Myocardial Infarction Disease Background and Overview
7. Acute Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Myocardial Infarction
9. Acute Myocardial Infarction Current Treatment and Medical Practices
10. Acute Myocardial Infarction Unmet Needs
11. Acute Myocardial Infarction Emerging Therapies
12. Acute Myocardial Infarction Market Outlook
13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034)
14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies
15. Acute Myocardial Infarction Market Drivers
16. Acute Myocardial Infarction Market Barriers
17. Acute Myocardial Infarction Appendix
18. Acute Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 minutes ago
- Globe and Mail
Dr. Sagy Grinberg Launches Nationwide Healing Hands Scholarship to Support Future Leaders in Healthcare
Dr. Sagy Grinberg Launches Nationwide Healing Hands Scholarship to Support Future Leaders in Healthcare New York City, NY - In a significant initiative aimed at fostering the growth of future healthcare leaders, board-certified physician Dr. Sagy Grinberg officially announces the Dr. Sagy Grinberg Healing Hands Scholarship for Healthcare. This nationwide scholarship is now open to undergraduate students across the United States who are pursuing careers in healthcare-related fields, including but not limited to medicine, nursing, public health, and biomedical sciences. With a well-established career in internal medicine and infectious diseases, Dr. Sagy Grinberg brings years of clinical experience and academic dedication to this philanthropic effort. As the lead physician of his own private practice, Dr. Sagy Grinberg has long understood the value of supporting emerging professionals who demonstrate both compassion and a commitment to evidence-based care. This scholarship marks a new chapter in his mission to help build a stronger, more innovative healthcare workforce. The Dr. Sagy Grinberg Healing Hands Scholarship for Healthcare invites undergraduate students currently enrolled at accredited U.S. institutions to submit an original essay addressing the following prompt: 'What inspires you to pursue a career in healthcare, and how do you plan to make a meaningful impact in the lives of others through your future work?' The essay should be between 750 and 1,000 words and reflect the applicant's personal motivation, vision, and potential contributions to the healthcare field. Applications must be submitted by January 15, 2026, and the selected recipient will be announced on February 15, 2026. Dr. Sagy Grinberg created this scholarship not only to reward academic ambition but also to recognize individuals who seek to bring about tangible, positive change in their communities through healthcare. 'The future of medicine relies on dedicated individuals with the heart and resilience to improve lives,' says Dr. Sagy Grinberg. 'This scholarship is designed to uplift those students and help them stay focused on their journey.' The scholarship is open to students nationwide without restriction to geographic location, offering a unique opportunity to applicants regardless of where they study in the United States. In addition to his practice in New York City, Dr. Sagy Grinberg has made considerable contributions to the fields of infection control, hospital and outpatient medicine, and medical research. He remains actively engaged in clinical advancement and continues to mentor rising medical professionals. Through this scholarship, he aims to provide financial assistance while also inspiring students to uphold high standards of patient care and clinical integrity. Interested applicants can learn more and apply via the official scholarship website: Media Contact Company Name: Dr. Sagy Grinberg Scholarship Contact Person: Dr. Sagy Grinberg Email: Send Email City: New York City State: New York Country: United States Website:
Globe and Mail
2 minutes ago
- Globe and Mail
Swanson Reed Achieves International ISO 27001 Security Certification
Swanson Reed, a respected U.S. R&D tax credit advisory firm, has obtained ISO 27001 certification, highlighting its dedication to protecting sensitive data and fostering client confidence. For more than 30 years, the company has served businesses nationwide, helping them claim R&D tax credits while now adding global security recognition to its credentials. ISO 27001 sets out stringent criteria for implementing an information security management system (ISMS). Certification confirms Swanson Reed's ability to safeguard client information, manage risks, and operate under best-practice standards. This milestone builds upon its ISO 31000:2009 Risk Management certification, further enhancing its operational credibility. Clients can trust that tools such as the AI-powered TaxTrex software and the creditARMOR audit defense program are supported by strong security measures. The firm processes over 1,500 R&D tax claims each year while maintaining the confidentiality of proprietary and financial data. Unlike one-time compliance efforts, ISO 27001 requires regular reviews and adjustments to keep pace with evolving cyber risks. Swanson Reed's systems are continually updated to remain resilient against emerging threats. The company also invests in secure infrastructure, multi-factor authentication, and real-time monitoring, ensuring its defenses are both preventive and responsive. 'Obtaining ISO 27001 certification is proof of our dedication to secure, reliable service delivery,' said Damian Smyth, CEO. 'We value the trust placed in us and work tirelessly to protect it.' As data security becomes an essential factor in choosing business partners, Swanson Reed's certification positions it as a leader in both innovation support and information protection. For more information, visit
Globe and Mail
32 minutes ago
- Globe and Mail
Digi Power X Reports Solid Mid-Year Financial Position, Removal of ‘Going Concern' Risk and Positive Adjusted EBITDA in Q2 2025
This news release constitutes a 'designated news release' for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (' Digi Power X ' or the ' Company ') (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company specializing in Tier 3 AI data centers, high-performance computing and sustainable digital asset operations, today announced its unaudited financial results for the three and six months ended June 30, 2025 (all amounts in U.S. dollars, unless otherwise indicated). The Company's unaudited consolidated financial statements and management's discussion and analysis (' MD&A ') for the three and six-month period ended June 30, 2025, have been filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at and are also available on the SEC's EDGAR website at Q2 Highlights Going Concern Removed – Significant balance sheet improvements have eliminated the 'going concern' risk previously disclosed in financial statements. Positive Adjusted EBITDA* achieved in Q2 2025, representing a major milestone toward sustainable profitability. Positive Working Capital Position Capital Raises – $6.6 million private placement + $4.5 million from warrant exercises = $12.9 million in Q2 2025. No long-term debts – Eliminated all loans payable and reduced accounts payable by more than $3.6 million since year-end 2024. Colocation revenue for the first six months of 2025 climbed to $9.57 million, a 163% increase year-over-year. Strategic & Operational Updates First B200 GPU Cluster Deployment on Track – In partnership with Super Micro Computers, Inc. (SMCI), the Company remains on schedule to have its first NVIDIA B200 GPU cluster fully operational by Q1 2026, marking a major milestone in its AI infrastructure roadmap. Advanced AI Customer Discussions – The Company is in advanced discussions with multiple AI customers to secure long-term infrastructure contracts, which are expected to increase revenue growth once finalized. Increased Energy Sales Revenue – Energy sales grew 127% year-over-year in Q2 2025 to $5.7 million, monetizing power assets alongside core colocation services. Operational Streamlining – Reduced cost of revenue and depreciation expenses by over $6.3 million compared to the first half of 2024, positioning the Company for improved margins ahead. Current Financial Position Strong Liquidity Position – As of today, Digi Power X holds over $30 million in cash, Bitcoin, Ethereum and cash equivalents, its strongest liquidity position in company history. Post-Quarter Capital Boost – Subsequent to quarter-end, the Company raised an additional $1.83 million through warrant exercises. 'The removal of the going concern risk and our achievement of over $30 million in cash and equivalents, including holdings of approximately 80 Bitcoin and 715 Ethereum, is a transformational moment for Digi Power X,' said Michel Amar, Chief Executive Officer of the Company. 'We now have the financial strength and operational momentum to capitalize on the rapidly expanding AI infrastructure market, with our first NVIDIA B200 GPU cluster set to go live in Q1 2026 and a pipeline of AI infrastructure contracts in advanced negotiations.' Looking ahead The Company expects continued strength in colocation and AI infrastructure deployments in the second half of 2025, supported by rising demand from enterprise AI, fintech and data-intensive sectors. Strong partnerships and enhanced liquidity position Digi Power X to pursue larger-scale projects, including planned expansions in Alabama and North Carolina. Digi Power X expects: Multiple AI customer contracts to be signed in Q4 2025 First B200 GPU cluster operational in Q4 2025/Q1 2026 Continued colocation and AI infrastructure growth supported by strong partnerships and expanded capacity Operations Update The Company currently operates with approximately 100MW of available power across its three sites and is working to expand its capacity to 200MW and beyond. The Company plans to fuel this growth using its existing asset portfolio, combined with strategic expansion through targeted acquisitions. At-the-Market Financing Update On May 30, 2025, the Company entered into an at-the-market sales agreement with A.G.P./Alliance Global Partners as sales agent (the 'Agent'), pursuant to which the Company established an at-the-market equity program (the 'ATM Program'). From the commencement of the ATM Program through June 30, 2025, the Company issued 806,291 subordinate voting shares in exchange for gross proceeds of $1,759,800, at an average share price of $2.13, and received net proceeds of $1,715,597 after paying commissions of $44,203 to the Agent. About Digi Power X Digi Power X is an innovative energy infrastructure company that develops data centers to drive the expansion of sustainable energy assets. For further information, please contact: Michel Amar, Chief Executive Officer Digi Power X Inc. Investor Relations T: 888-474-9222 Email: IR@ Cautionary Statement Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements Except for the statements of historical fact, this news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking information') that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the timeline for implementing its strategic plans, including as part of its various partnerships; the strength of demand for AI-related and colocation services; the issuance of a patent in respect of the ARMS system, deployment of the NVIDIA Blackwell 200 GPUs and the timing for and impact of that deployment potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: results of provisional utility patent application are uncertain and may not result as anticipated by Company, including the issuance of a nonprovisional utility patent, which may not occur on a timely basis or at all; delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company, or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; effects on Bitcoin prices as a result of the most recent Bitcoin halving; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid and realize the potential of the clean energy strategy on terms which are economic or at all; a decrease in cryptocurrency pricing, volume of transaction activity or generally, the profitability of cryptocurrency mining; further improvements to profitability and efficiency may not be realized; development of additional facilities to expand operations may not be completed on the timelines anticipated by the Company; ability to access additional power from the local power grid; an increase in natural gas prices may negatively affect the profitability of the Company's power plant; the digital currency market; the Company's ability to successfully mine digital currency on the cloud; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at and The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, the current profitability in mining cryptocurrency (including pricing and volume of current transaction activity); profitable use of the Company's assets going forward; the Company's ability to profitably liquidate its digital currency inventory as required; historical prices of digital currencies and the ability of the Company to mine digital currencies on the cloud will be consistent with historical prices; the ability to maintain reliable and economical sources of power to run its cryptocurrency mining assets; the negative impact of regulatory changes in the energy regimes in the jurisdictions in which the Company operates; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law. * ADJUSTED EBITDA – NON-IFRS MEASURE Adjusted EBITDA is a non-IFRS financial measure and should be read in conjunction with and should not be viewed as an alternative to or replacement of measures of operating results and liquidity presented in accordance with IFRS. Readers are referred to the reconciliations of non-IFRS measures included in the Company's MD&A and in the table below. The following table provides a reconciliation of net income to Adjusted EBITDA for the first two quarters of 2025: Q2 2025 Q1 2025 $ $ Loss before other items (10,385,750) (1,688,532) Taxes and Interest 20,390 (6,923) Depreciation 1,573,691 2,172,791 Revaluation of warrant liabilities 3,431,921 (2,919,893) FX 3,538,930 63,294 FV Changes (450,288) 109,966 Share based compensation 2,069,041 1,038,785 Adjusted EBITDA 248,223 (1,340,478) (U.S.$ in thousands except per share data) Six Months Ended June 30 2025 June 30 2024 Revenue from digital currency mining 2,161 9,779 Revenue from colocation services 9,570 3,637 Revenue from sale of electricity - 6,283 Revenue from sale of energy 5,657 2,490 Cost of sales (15,252) (17,177) Depreciation and amortization (3,746) (7,903) Gross profit (loss) (1,611) (2,890) General and administrative and other expenses (3,886) (2,262) Foreign exchange (3,602) 2,003 Gain on disposition of cryptocurrencies 654 271 Change in FV of loan payable and salaries payable (283) (20) Other Income - 14 Share based compensation (3,108) (750) Gain on revaluation of digital currencies 286 49 Operating loss (11,549) (3,586) Revaluation of warrant liabilities (512) 3,682 Net financial expenses (13) (17) Net loss before income taxes (12,074) 79 Deferred tax (expense) recovery - - Net income (loss) for the year (12,074) 79 Foreign currency translation adjustment 3,205 (1,847) Revaluation of digital currency, net of tax - - Total comprehensive income (loss) for the year (8,869) (1,768) Basic and diluted income (loss) per share (0.34) 0.00 Weighted average number of subordinate voting shares outstanding – diluted 35,799,779 29,297,364
